CRMD: CorMedix Inc. Stock

by  •  • Comments Off on CRMD: CorMedix Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 815.25
Enterprise Value ($M) 748.97
Book Value ($M) 114.89
Book Value / Share 1.69
Price / Book 7.10
NCAV ($M) 110.17
NCAV / Share 1.62
Price / NCAV 7.40

Profitability (mra)
Return on Invested Capital (ROIC) 0.15
Return on Assets (ROA) 0.25
Return on Equity (ROE) 0.30

Liquidity (mrq)
Quick Ratio 3.99
Current Ratio 4.21

Balance Sheet (mrq) ($M)
Current Assets 144.86
Assets 149.58
Liabilities 34.69
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 43.47
Operating Income -22.36
Net Income -17.93
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -50.61
Cash from Investing 21.23
Cash from Financing 26.32

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-04 13G Shaibatalhamd Aymen Abdalkader 5.40
02-05 13G/A BlackRock, Inc. 7.50 30.23
11-14 13G/A Nomura Holdings Inc 0.30 -94.25

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P
2025-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTIO
2024-10-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-08 850,110 7,910,595 10.75
2025-05-07 922,396 6,561,193 14.06
2025-05-06 602,451 3,931,265 15.32
2025-05-05 458,166 1,749,125 26.19

(click for more detail)

Similar Companies
CHRS – Coherus BioSciences, Inc. CLSD – Clearside Biomedical, Inc.
CLYM – Climb Bio, Inc. CRON – Cronos Group Inc.
CRSP – CRISPR Therapeutics AG


Financial data and stock pages provided by
Fintel.io

Finpedia: CorMedix